You are here

Life Ethics

Abortion

We will avoid investing in:

  • Companies that own and/or operate one or more acute care hospitals or surgical centres that provide abortion services;
  • Companies that manufacture abortifacients, a class of drugs that can be used either singly or in combination with other drugs to terminate a pregnancy. This screen does not exclude producers of medications such as misoprostyl and methotrexate, which, although sometimes used to induce abortion, were developed and are marketed for other purposes.

Contraceptives

  • We will avoid investing in companies that derive 25% or more of their revenues from the manufacture contraceptives including diaphragms, intrauterine devices (IUDs), oral contraceptives, spermicides, cervical caps, contraceptive implants, contraceptive patches and contraceptive vaccines. This screen does not exclude the manufacturers of condoms.

Embryonic Stem Cell and fetal tissue Research

While the OIP supports research that utilizes adult or somatic stem cells, we will avoid investing in:

  • Companies involved in the use of embryonic stem cells or tissue derived from human embryos or fetuses.
  • This includes, but is not limited to, human embryonic stem cell research into treatments and/or therapies for diseases such as cancer, heart disease and diabetes. Embryonic stem cells are pluripotent cells that can differentiate into any cell of the body and are derived from the inner cell mass of the blastocyst, an early-stage embryo that reaches this stage 4-5 days post fertilization.
  • Companies involved in the use of fetal cell lines for vaccine or biologics development. This includes, but is not limited to, the use of fetal cell lines for vaccines for flu, mmr, hepatitis A & B, smallpox, chicken pox and shingles along with tumor vaccines. Fetal cell lines are not stem cells, but are derived from a fetus and then replicated to create cell lines that can be used indefinitely. The WI-38 and MRC-5 lines are the most widely used.
  • Companies develop technologies that enable embryonic stem cell research. This includes, but is not limited to, technologies that improve extraction and preservation of human embryonic stem cells or technology that isolates or regulates the growth of stem cells.
  • Companies that have an ownership interest in another company involved in embryonic stem cell research. This screen does not exclude investment management firms owning less than 10% of equity.